Miromatrix Medical Inc. Research and Development Expense
Miromatrix Medical Inc. reported Research and Development Expense of $3.51 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-11-14
- Miromatrix Medical Inc. research and development expense for the quarter ending 2023-09-30 was $3.51M, a 23.36% decline year-over-year.
- Miromatrix Medical Inc. research and development expense for the quarter ending 2023-06-30 was $3.62M, a 27.40% decline year-over-year.
- Miromatrix Medical Inc. research and development expense for the quarter ending 2023-03-31 was $4.39M, a 9.62% increase year-over-year.
- Miromatrix Medical Inc. research and development expense for the quarter ending 2022-12-31 was $4.73M, a 54.85% increase year-over-year.
- Miromatrix Medical Inc. research and development expense for fiscal 2022 was $18.30M, a 70.17% increase from fiscal 2021.
- Miromatrix Medical Inc. research and development expense for fiscal 2021 was $10.76M, a 47.73% increase from fiscal 2020.
- Miromatrix Medical Inc. research and development expense for fiscal 2020 was $7.28M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-09-30 | $3.51M 10-Q · filed 2023-11-14 | $7.13M derived: sum of 2 quarters · filed 2023-11-14 | $11.52M 10-Q · filed 2023-11-14 | $16.25M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2023-06-30 | $3.62M 10-Q · filed 2023-08-14 | $8.01M 10-Q · filed 2023-08-14 | $12.75M derived: sum of 3 quarters · filed 2023-08-14 | $17.32M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2023-03-31 | $4.39M 10-Q · filed 2023-05-11 | $9.13M derived: sum of 2 quarters · filed 2023-05-11 | $13.70M derived: sum of 3 quarters · filed 2023-11-14 | $18.69M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-12-31 | $4.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $9.31M derived: sum of 2 quarters · filed 2023-11-14 | $14.30M derived: sum of 3 quarters · filed 2023-11-14 | $18.30M 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $4.57M 10-Q · filed 2023-11-14 | $9.56M derived: sum of 2 quarters · filed 2023-11-14 | $13.57M 10-Q · filed 2023-11-14 | $16.63M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $4.99M 10-Q · filed 2023-08-14 | $8.99M 10-Q · filed 2023-08-14 | $8.99M 10-Q · filed 2022-08-15 | $12.05M derived: sum of 3 quarters · filed 2023-08-14 | $15.40M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $4.01M 10-Q · filed 2023-05-11 | $4.01M 10-Q · filed 2022-05-16 | $7.06M derived: sum of 2 quarters · filed 2023-05-11 | $10.41M derived: sum of 3 quarters · filed 2023-05-11 | $12.89M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $6.41M derived: sum of 2 quarters · filed 2023-03-31 | $8.89M derived: sum of 3 quarters · filed 2023-03-31 | $10.76M 10-K · filed 2023-03-31 | $10.75M 10-K · filed 2022-03-30 | ||
| 2021-09-30 | $3.35M 10-Q · filed 2022-11-14 | $5.83M derived: sum of 2 quarters · filed 2022-11-14 | $7.70M 10-Q · filed 2022-11-14 | $9.23M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $2.48M 10-Q · filed 2022-08-15 | $4.35M 10-Q · filed 2022-08-15 | $5.88M derived: sum of 3 quarters · filed 2022-08-15 | $7.75M derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | $1.87M 10-Q · filed 2022-05-16 | $3.40M derived: sum of 2 quarters · filed 2022-05-16 | $5.27M derived: sum of 3 quarters · filed 2022-05-16 | $7.35M derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $3.40M derived: sum of 2 quarters · filed 2022-03-30 | $5.48M derived: sum of 3 quarters · filed 2022-03-30 | $7.28M 10-K · filed 2022-03-30 | |||
| 2020-09-30 | $1.87M 10-Q · filed 2021-11-15 | $3.95M derived: sum of 2 quarters · filed 2021-11-15 | $5.75M 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $2.08M 10-Q · filed 2021-08-12 | $3.88M 10-Q · filed 2021-08-12 |